Valneva Stock

Valneva EBITDA per Employee

The EBITDA per Employee of Valneva (VLA.PA) as of Aug 23, 2026 is -160,690.94 EUR. In the previous year, EBITDA per Employee was 40,807.09 EUR — a change of -493.78% (lower).

EBITDA per Employee

-160,690.94EUR

YoY

-493.78%

Last updated:

EBITDA per Employee of Valneva is 2026 -160,690.94 EUR. EBITDA per Employee of Valneva was 2025 40,807.09 EUR. It decreases by -493.78% lower compared to the previous year.

The Valneva EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
20,850.39 EUR
Jan 1, 2019
11,746.06 EUR
Jan 1, 2020
-97,996.06 EUR
Jan 1, 2021
-94,222.44 EUR
Jan 1, 2022
-238,427.17 EUR
Jan 1, 2023
-142,153.54 EUR
Jan 1, 2024
40,807.09 EUR
Jan 1, 2025
-160,690.94 EUR
The Valneva EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-160,690.94EUR-493.78%
40,807.09EUR-128.71%
-142,153.54EUR-40.38%
-238,427.17EUR+153.05%
-94,222.44EUR-3.85%
-97,996.06EUR-934.29%
11,746.06EUR-43.67%
20,850.39EUR+29.36%
16,118.11EUR-647.69%
-2,942.91EUR-88.19%
-24,923.23EUR+10.15%
-22,625.98EUR
Access this data via the Eulerpool API

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

EBITDA per Employee of Valneva is -160,690.94 EUR in 2026.

EBITDA per Employee of Valneva changed from 40,807.09 EUR to -160,690.94 EUR, representing a -493.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Valneva since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Valneva historically and in real time.

Access this data via the Eulerpool API

Workforce — Valneva

All Key Metrics — Valneva